The abstract is read at the publisher; the summary is JClub's.
SKLB-39b, a BRD4-BD1-selective inhibitor, restores protective autophagy and attenuates pulmonary fibrosis in experimental models, with over 100-fold BRD4-BD1 selectivity.
- Why it matters: Impaired protective autophagy contributes to idiopathic pulmonary fibrosis, but therapies that restore this process are limited.
- What they did: The study identified a BRD4-BD1–p62 interaction and used SKLB-39b to disrupt it via Leu92 and Ile146 binding, restoring ULK1-dependent autophagy and testing effects in experimental fibrosis versus JQ-1.
- The result: SKLB-39b suppressed fibroblast activation, epithelial-mesenchymal transition, and collagen deposition, showed favorable pharmacokinetic exposure, and had no overt toxicity in mouse studies, supporting BRD4-BD1–p62 as a druggable target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.